Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease

Neurobiology of Disease

Volumn 39, Issue 3, 2010, Pages 311-317

  Braithwaite, Steven P ^a   Schmid, Ralf S ^b   He, Dong Ning ^b   Sung, Mei Li A ^a   Cho, Seongeon ^a   Resnick, Lynn ^a   Monaghan, Michael M ^a   Hirst, Warren D ^a   Essrich, Christian ^b   Reinhart, Peter H ^a   Lo, Donald C ^b  

^a PFIZER INC   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

APP; Biolistics; Brain slice; Drug discovery; JNK; Neurodegeneration; Neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN; STRESS ACTIVATED PROTEIN KINASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLISTIC TRANSFORMATION; BRAIN SLICE; CONTROLLED STUDY; ENZYME INHIBITION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RAT; SENILE PLAQUE; TRANSGENIC MOUSE;

EID: 77954955175     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.04.015     Document Type: Article

References (43)

1. Barr R.K., et al. Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. 2002, 277:10987-10997.
2. Bennett B.L., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:13681-13686.
3. Bogoyevitch M.A., et al. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta 2004, 1697:89-101.
4. Borsello T., et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 2003, 9:1180-1186.
5. Brecht S., et al. Specific pathophysiological functions of JNK isoforms in the brain. Eur. J. Neurosci. 2005, 21:363-377.
6. Cho S., et al. Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr. Neuropharmacol. 2007, 5:19-33.
7. Colombo A., et al. The TAT-JNK inhibitor peptide interferes with beta amyloid protein stability. Cell Death Differ. 2007, 14:1845-1848.
8. Colombo A., et al. JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. Neurobiol. Dis. 2009, 33:518-525.
9. Crittenden J.R., et al. CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease. Hum. Mol. Genet. 2010, 19:1756-1765.
10. Dhanasekaran D.N., Reddy E.P. JNK signaling in apoptosis. Oncogene 2008, 27:6245-6251.
11. Fisher M., et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250.
12. Flood D.G., et al. FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol. Aging 2002, 23:335-348.
13. Himmler A., et al. Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol. Cell. Biol. 1989, 9:1381-1388.
14. Holcomb L., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998, 4:97-100.
15. Huang H.C., Jiang Z.F. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J. Alzheimers Dis. 2009, 16:15-27.
16. Khoshnan A., et al. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci. 2004, 24:7999-8008.
17. Kumagae Y., et al. Human c-Jun N-terminal kinase expression and activation in the nervous system. Brain Res. Mol. Brain Res. 1999, 67:10-17.
18. Lee G., et al. The primary structure and heterogeneity of tau protein from mouse brain. Science 1988, 239:285-288.
19. Lo D.C. Neuronal transfection using particle-mediated gene transfer. Curr. Protocol. Neurosci. 1999, 3:1-12.
20. Morishima Y., et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 2001, 21:7551-7560.
21. Pu J., et al. Synthesis and structure-activity relationship of a novel series of heterocyclic sulfonamide gamma-secretase inhibitors. Bioorg. Med. Chem. 2009, 17:4708-4717.
22. Puig B., et al. Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA plaques in APP Tg2576 mice. Neuropathol. Appl. Neurobiol. 2004, 30:491-502.
23. Quiroz-Baez R., et al. Oxidative stress promotes JNK-dependent amyloidogenic processing of normally expressed human APP by differential modification of [alpha]-, [beta]- and [gamma]-secretase expression. Neurochem. Int. 2009, 55:662-670.
24. Ren Z., et al. Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. J. Biol. Chem. 2007, 282:35350-35360.
25. Reynolds C.H., et al. Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. J. Neurochem. 1997, 68:1736-1744.
26. Sagisaka T., et al. Directed neural lineage differentiation of adult hippocampal progenitor cells via modulation of hippocampal cholinergic neurostimulating peptide precursor expression. Brain Res. 2010, 1327:107-117.
27. Salloway S., et al. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 2008, 4:65-79.
28. Savage M.J., et al. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J. Neurosci. 2002, 22:3376-3385.
29. Schneider A., Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 2008, 5:443-457.
30. Shen C., et al. Hydrogen peroxide promotes Aβ production through JNK-dependent activation of β-secretase. Vol. 2008, 283:17721-17730.
31. Southwell A.L., et al. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J. Neurosci. 2008, 28:9013-9020.
32. Tamagno E., et al. JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol. Aging 2009, 30:1563-1573.
33. Thompson L.M., et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 2009, 187:1083-1099.
34. Vardy E.R., et al. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol. Med. 2005, 11:464-472.
35. Varma H., et al. Selective inhibitors of death in mutant huntingtin cells. Nat. Chem. Biol. 2007, 3:99-100.
36. Varma H., et al. Selective inhibitors of death in mutant huntingtin cells. Nat. Chem. Biol. 2007, 3:99-100.
37. Vogel J., et al. The JNK pathway amplifies and drives subcellular changes in tau phosphorylation. Neuropharmacology 2009, 57:539-550.
38. Walker D., Lue L.F. Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. Curr. Neuropharmacol. 2007, 5:232-243.
39. Wang J.K., et al. Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10461-10466.
40. Yacoubian T.A., Lo D.C. Truncated and full-length TrkB receptors regulate distinct modes of dendritic growth. Nat. Neurosci. 2000, 3:342-349.
41. Yang D.D., et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997, 389:865-870.
42. Yoshida H., et al. Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). J. Neurochem. 2004, 90:352-358.
43. Zlokovic B.V. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 2008, 5:409-414.